merged_alzheimers-treatment-kisunla-donanemab.txt
<question_number>1</question_number>
<answer>significant safety risks such as brain swelling and bleeding despite only modest benefit</answer>
<question_number>2</question_number>
<answer>emphasis on anti-amyloid drugs may discourage patients from joining trials of other potential therapies, slowing progress</answer>
<question_number>3</question_number>
<answer>no correlation between amyloid removal and clinical response in individual patients</answer>
<question_number>4</question_number>
<answer>higher swelling and bleeding rates could heighten concerns and make Kisunla appear less safe</answer>
<question_number>5</question_number>
<answer>patients can stop treatment once amyloid is cleared, so shorter therapy duration is expected to offset the higher annual price</answer>
<question_number>6</question_number>
<answer>could deter patients from enrolling in other clinical trials</answer>
<question_number>7</question_number>
<answer>monthly dosing that can be discontinued after plaques clear reduces infusion frequency and duration</answer>
<question_number>8</question_number>
<answer>amyloid</answer>
<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>
<question_number>10</question_number>
<answer>patients with intermediate tau levels benefited more than those with high tau levels</answer>